iCAD, Inc. is an industry-leading provider of Computer-Aided Detection
(CAD) solutions that enable healthcare professionals to identify cancer and
other life-threatening conditions earlier by making medical services more
effective, more accessible and more affordable for patients worldwide.
A recipient of Frost & Sullivan's Growth Strategy Leadership award, iCAD
offers a comprehensive range of high-performance, upgradeable CAD systems
for the high, mid and low volume mammography markets.
The Company is entrusted with the task of early cancer detection by over
eleven hundred women's healthcare centers worldwide.
iCAD, Inc. is headquartered in Nashua, New Hampshire and its stock is
listed on The Nasdaq Stock Market.